LCS
AMRI

Levin Capital Strategies’s Albany Molecular Research Inc AMRI Stock Holding History

Levin Capital Strategies’s Portfolio AMRI Stock Details AMRI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-50,048
Closed -$1.01M – 414
2015
Q2 		$1.01M Sell
50,048
-63,155
-56% -$1.22M 0.02% 204
2015
Q1 		$1.99M Buy
+113,203
New +$1.93M 0.03% 171
2014
Q2 		– Sell
-32,115
Closed -$597K – 382
2014
Q1 		$597K Buy
+32,115
New +$442K 0.01% 253

Other funds holding AMRI

VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
PIP
Permian Investment Partners Dallas, Texas $905M AUM 13.43% 1-Year Est. Return
OWP
Obermeyer Wealth Partners Aspen, Colorado $2.17B AUM 19.33% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EWM
Evercore Wealth Management New York $6.36B AUM 20.35% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Levin Capital Strategies's AMRI Position: Q3 2015 in Review

Levin Capital Strategies sold out of Albany Molecular Research Inc (AMRI) in Q3 2015, closing a stake of 50,048 shares — an estimated $1.01M sold.

Levin Capital Strategies first reported a position in AMRI in Q1 2014 and held it in 3 quarters. The position peaked at $1.99M in Q1 2015. 143 funds tracked by Wall St. Rank hold AMRI as of Q3 2015.

  • Levin Capital Strategies reported no remaining Albany Molecular Research Inc position as of Q3 2015 after selling out during the quarter.
  • Levin Capital Strategies sold 50,048 Albany Molecular Research Inc shares in Q3 2015, an estimated $1.01M.
  • Levin Capital Strategies first reported a position in Albany Molecular Research Inc in Q1 2014 and held it in 3 quarters.
  • Levin Capital Strategies's Albany Molecular Research Inc position peaked at $1.99M in Q1 2015.
  • 143 funds tracked by Wall St. Rank held Albany Molecular Research Inc as of Q3 2015.

Based on Levin Capital Strategies's 13F filing for Q3 2015, filed 13 Nov 2015.